The following video is part of our "Motley Fool Conversations" series, in which health-care editor and analyst David Williamson and consumer goods editor and analyst Austin Smith discuss topics across the investing world.
In this edition, David and Austin catch up on popular biotech Cell Therapeutics. The company has seen huge share price swings recently, first down 20% after pulling Pixuvri's application from the FDA before an advisory panel could weigh in, and then up a similar amount after a European advisory panel recommended approval. Find out what these events really mean for the company and for investors.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time thisarticle was published Austin Smith has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.